Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101657 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL658272 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL29434936 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL658927 | 1.00 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL659851 | 0.95 | MDM2 (0.91) | MDM2TP53 | |
| SCHEMBL659850 | 0.95 | MDM2 (0.91) | MDM2TP53 | |
| SCHEMBL660812 | 0.95 | MDM2 (0.90) | MDM2TP53 | |
| SCHEMBL660813 | 0.95 | MDM2 (0.90) | MDM2TP53 | |
| SCHEMBL660458 | 0.94 | MDM2 (1.00) | MDM2TP53 | |
| SCHEMBL658747 | 0.94 | MDM2 (0.90) | MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | claimed |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2019183523-A1 | HETERO-BIFUNCTIONAL DEGRADER COMPOUNDS AND THEIR USE AS MODULATORS OF TARGETED UBIQUINATION (VHL) | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20130053410-A1 | SUBSTITUTED HETEROARYL 2',3',7',7A'-TETRAHYDROSPIRO[PYRROLE-3,6'-PYRROLO[1,2-C]IMIDAZOLE]-1',2(1H,5'H)-DIONE | BARTKOVITZ DAVID JOSEPH (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2012116989-A1 | SUBSTITUTED HETEROARYL 2', 3', 7', 7A' - TETRAHYDROSPIRO-[PYRROLE-3, 6' - PYRROLO [1, 2-C] IMIDAZOLE] - 1', 2 (1H, 5'H) -DIONES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012022707-A1 | SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | VHL, MDM2, CUL2 | MDM2 2/4885TP53 35/4885 |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | VHL, MDM2, CUL2 | MDM2 2/4885TP53 35/4885 |
| US-20130053410-A1 | SUBSTITUTED HETEROARYL 2',3',7',7A'-TETRAHYDROSPIRO[PYRROLE-3,6'-PYRROLO[1,2-C]IMIDAZOLE]-1',2(1H,5'H)-DIONE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PYCR1, DHPS | MDM2 411/4885TP53 43/4885 |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | MDM2, TP53, RB1 | MDM2 1/4885TP53 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.